Payment & Shipping Terms:
|CAS:||668270-12-0||Package:||Aluminum Foil Bag|
|Production Capacity:||500 Kilogram/month||Storage:||Kept In A Cool,dry And Ventilated Place|
Linagliptin Research Chemicals,
668270-12-0 Research Chemicals,
C25H28N8O2 Research Chemicals
99% China Supply Linagliptin CAS 668270-12-0 Linagliptin Powder Linagliptin with Superior for Antidiabetic
|Linagliptin Basic information|
|Uses Treatment of Type 2 diabetes Pharmacokinetics|
|Synonyms:||linagliptin;8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione;(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione;1H-Purine-2,6-dione, 8-((3R)-3-amino-1-piperidinyl)-7-(2-butynyl)-3,7-dihydro-3-methyl-1-((4-methyl-2-quinazolinyl)methyl)-;Bi 1356;Ondero;8-[(3R)-3-AMino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-Methyl-1-[(4-Methyl-2-quinazolinyl)Methyl]-1H-purine-2,6-dione;8-[(3R)-3-AMino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-Methyl-1-[(4-Methyl-2-quinazolinyl)Methyl]-1H-purine-2,6-d|
|Product Categories:||TRADJENTA;Linagliptin;Amines;API;Pharmaceutical raw material;Inhibitor;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals|
Linagliptin is a kind of dipeptide peptidase 4 (DPP - 4) inhibitors used as dietary and exercise in type 2 diabetes in adult auxiliary treatment to improve blood sugar control.
Linagliptin is used with a proper diet and exercise program and possibly with othermedications to control high blood sugar. It is used by people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke.
99% CAS 668270-12-0 Linagliptin Ondero for Type 2 Diabetes
1. Incretin (Incretin) has the role of intestinal promoting insuli n B cells to secrete insuli n, mainly including glucose-dependent insuli notropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). DDP-4 is a serine protease located on the cell surface, which is widely found in plasma and in vivo tissues (such as kidney, liver, small intestine villi, endothelial cells, etc.). Rilalitine is a selective DPP-4 inhibitor that inhibits the activity of the enzyme by reversibly binding to DPP-4, delays GLP-1 degradation, enhances GLP-1 activity, and stimulates glucose-dependent Insuli n secretion, and reduce circulating levels of glucagon, thereby regulating blood glucose levels in patients with type 2 diabetes.
2. Compared with other DPP-4 inhibitors, the main advantages of liradetine is: with excellent renal safety, and can effectively reduce glycosylated hemoglobin. Lilardine mainly in the form of excretion of fecal excretion, the oral administration, the amount of renal excretion is only 5% of the dose, even if the intravenous administration, and only 30.8% of the excretion by the kidney, so the patient did not need treatment Regularly check the liver, kidney function and dose adjustment, all patients can be a unified fixed dose, easy to prescribe.
Contact Person: July